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Abstract
This study aimed to investigate the therapeutic effects of intranasal administration of human endometrium-derived stem cells 
(HEDSCs) in the mouse model of Parkinson’s disease (PD). Thirty days after intrastriatal injection of 6-OHDA, HEDSCs 
were administrated intranasally in three doses  (104, 5 × 104 and  105 cells µl−1). During 120 days after stem cell administration, 
behavioral tests were examined. Then the mice were sacrificed and the fresh section of the substantia nigra pars compacta 
(SNpc) was used for detection of HEDSCs-GFP labeled by fluorescence microscopy method. In addition, immunohisto-
chemistry was used to assay GFP, human neural Nestin, and tyrosine hydroxylase (TH) markers in the fixed brain tissue at 
the SNpc. Our data revealed that behavioral parameters were significantly improved after cell therapy. Fluorescence micros-
copy assay in fresh tissue and GFP analysis in fixed tissue were showed that the HEDSCs-GFP labeled migrated to SNpc. 
The data from immunohistochemistry revealed that the Nestin as a differential neuronal biomarker was expressed in SNpc. 
Also, TH as a dopaminergic neuron marker significantly increased after HEDSCs therapy in an optimized dose 5 × 104 cells 
µl−1. Our results suggest that intranasal administration of HEDSCs improve the PD symptoms in the mouse model of PD 
dose-dependent manner as a noninvasive method.
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Introduction
Mesenchymal stem cells (MSCs) have presented their capa-
bility to induce synaptic formation, enhance endogenous 
neural development, multipotency and nonhematopoietic 
aspects [1, 2]. These cells can differentiate into the mes-
enchymal lineage such as cartilage, dopaminergic neurons, 
bone, adipose tissue, muscle, and tendon [3]. MSCs do not 
induce proliferative responses of lymphocytes that propose 
they have a little immunogenicity and might pass the rejec-
tion of immune system [4–6]. Due to their self-renewal, 
differentiation, and immune-suppressive capacities, MSCs 
could be a potential candidate for cell therapy in several 
disorders such as neurological diseases [7, 8]. Some studies 
have emphasized the MSCs capacity to contribute in repair-
ing of central nervous system (CNS) in experimental models 
of stroke, multiple sclerosis, amyotrophic lateral sclerosis 
(ALS), trauma, Alzheimer’s disease (AD), and Parkinson’s 
disease (PD) [9, 10]. Neurodegenerative diseases including 
PD cause debilitating state specified by progressive degen-
eration of particular neurons in the brains of patients. The 
Parkinson’s Foundation estimates seven to ten million per-
sons around the world are existing with PD [11]. Common 
clinical therapies are including the oral administration of 
some dopamine receptor agonists such as levodopa and deep 
stimulation of brain in the subthalamic nucleus. However, 
long-term levodopa therapy is correlated with several side 
effects and consecutive surgical and medical interventions 
lead to be stopped the disease progression. Otherwise, stem 
cell technology holds major promise in PD therapy [1]. 
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Human endometrium-derived stem cells (HEDSCs) are a 
type of MSCs which recently characterized and they repre-
sent a new cell source for neurological disorders [12, 13]. 
An active target of these stem cells is PD as a chronic, pro-
gressive, and neurodegenerative disease that debilitates both 
motor function and speech due to the insufficient production 
of dopamine by pigmented cells in the substantia nigra pars 
compacta (SNpc) [14–16]. HEDSCs are capable to differ-
entiate into dopaminergic neuron-like cells in vitro which 
display axon-like and dendritic-like projections and they 
express neural cell markers such as tyrosine hydroxylase 
(TH) and human Nestin [1–17]. Preclinical examinations 
have shown that intravenous or intracerebral administration 
of MSCs could improve the efficient retrieval in PD. Admin-
istration of stem cells in a systemic is a non-invasive deliv-
ery way compared to surgical method. The adverse events 
of surgical transplantation is consisting the infection and 
tumorigenicity risks [18]. To improve homing efficacy and 
MSCs persistence in the CNS by means of a non-invasive 
process, we assumed that MSCs could be targeted to the 
CNS and inhibit local inflammation upon intranasal delivery 
of them. Therefore, intranasal delivery of HEDSCs could 
open a therapeutic strategy by saving dopaminergic neurons 
in PD. HEDSCs therapeutic strategy will be a more impor-
tant issue with subject to current therapies have not been 
able to regenerate the lost cells [17–20]. Here we studied the 
therapeutic effects of intranasal administration of HEDSCs 
in the mouse unilateral 6-OHDA lesioned model of PD.
Methods
Animals and 6‑OHDA mouse model
A total of 35 male mice (age: 2 months, weight: 25–30 
g, species: NMRI) were provided from the Experimental 
Research Center of Kashan University of Medical Sciences 
(Kashan, Iran) and maintained in following conditions: tem-
perature of 23–25 °C, humidity of 50–55%, and 12 h dark/
light cycle. All experiments were performed according to the 
Guidelines for the Care and Use of Mammals in Neurosci-
ence (2003).
Adult male mice were anesthetized by an intraperito-
neal (i.p) injection of Ketamine (90–120 mg/Kg) through 
with Xylazine (10 mg/Kg). Animals were positioned on 
the stereotaxic frame using mouth-piece and ear bars 
specially designed for this species. A sterilized Hamilton 
syringe (type SGC, volume 5 μl, gauge 26 s) containing 4 μl 
6-OHDA solution (Sigma–Aldrich, Chemie GmbH, H4381) 
vertically was aligned in the stereotaxic apparatus. The tip of 
the needle is then inserted into the opened hole and slowly 
lowered to reach the coordinates of the striatum (AP: +0.5; 
L: − 2.0; DV: − 3.0 mm) and then injected with a flow rate 
of 0.5 μl/min [21].
Based on the previous studies, this research was done to 
investigate the dose-dependent therapeutic effects of stem 
cells on PD mice model [22]. The animals were divided 
into five groups (containing seven mice for each) as follows: 
1- control group containing healthy mice which intranasally 
received PBS, 2- 6-OHDA group containing PD mice which 
intranasally received PBS, 3- Treat 1 (T1) group containing 
PD mice which intranasally received HEDSCs in  104 cells 
µl−1 dose, 4- Treat 2 (T2) group containing PD mice which 
intranasally received HEDSCs in 5 × 104 cells µl−1 dose, 5- 
Treat 3 (T3) group containing PD mice which intranasally 
received HEDSCs in  105 cells µl−1 dose.
Behavioral evaluation
To evaluate the therapeutic effects of intranasal delivery 
of HEDSCs, neurobehavioral testing of all animals was 
performed by monitoring their general activity, rotarod 
test, akinesia and cataplexy as well as rotational behavior. 
The following behaviorial tests were performed in separate 
groups of animals (Cell-treated groups vs. control group or 
6-OHDA group).
Rotational behavior On days 30, 60, 90 and 120 after cell 
therapy, the rotational behavior was measured in a rotameter 
system. Animals received an i.p injection of apomorphine 
(0.5 mg/kg, Apomorphine hydrochloride hemihydrates, 
Sigma–Aldrich, St. Louis, MO, USA), and were placed in 
an opaque cylinder. After 5 min habituation, full-body con-
tralateral rotations were recorded in a 10 min timeframe for 
1 h. In the treatment groups, full-body rotations were meas-
ured and compared with the 6-OHDA group. The animals 
could be safely returned to their housing 60 min after the 
test [21, 23].
Akinesia To measure the Akinesia, we were recorded the 
latency of the animals to move all four limbs, and the test 
was terminated when the latency exceeded 180 s [24, 25].
Catalepsy Catalepsy defined as the inability of rodents 
to correct an externally imposed posture. In this item, we 
placed the mice on a flat horizontal surface with two hind 
limbs on a square wooden block with 3 cm hight, and the 
latency to move of hind limbs from the block to the ground 
was measured in each second [25].
Rotarod test Motor function was analyzed using a rotarod 
apparatus. All animals were pretrained at four rpm on the 
rotarod apparatus to make them attain a stable performance 
and later at 10 rpm until falling on the grids beneath the 
rotating roller. This test was progressed for 10 min.
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Endometrial sample collection
After obtaining informed consent form, human endometrial 
stem cells (HEDSCs) were collected from ten women under-
going surgery for benign gynaecological conditions. Normal 
endometrial stem cells were cultured in a routine fashion 
which produced an unfractionated stromal cell population. 
For this purpose, we minced endometrial tissue and then 
digested them in HBSS (Gibco, Invitrogen, Carlsbad, CA, 
USA) containing HEPES (25 mM), collagenase B (1 mg/
ml, Roche Diagnostics, Indianapolis, IN, USA) and DNase 
I (0.1 mg/ml, Sigma-Aldrich, St. Louis, MO, USA) for 
35–40 min in 37 °C. To remove glandular epithelial com-
ponents, we were passed dispersed cell solutions through a 
70 µM sieve (BD Biosciences, Bedford, MA, USA). After 
resuspending the supernatant in Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco, Invitrogen) and Ham’s F12 with 
phenol red containing 1% antimycotics-antibiotics (ABAM, 
Gibco, Invitrogen) and 10% fetal bovine serum (FBS, 
Gibco, Invitrogen), cell solutions were filtered and centri-
fuged. Resuspended cells were then plated in plastic flasks 
and incubated at 37 °C and 5% CO2. Culture medium was 
changed every day and thereafter, cells were passaged using 
standard trypsinization methods. After passage two, cell cul-
tures derived from human endometrial tissue were character-
ized using flow cytometry method. HEDSCs display strong 
positivity for MSCs markers such as  CD146+/PDGFRβ+ and 
 SUSD2+. As shown in Fig. 1A, HEDSCs exhibited in vitro 
typical stromal cell morphology.
GFP transfection of HEDSCs and stem cell 
administration
HEDSCs were GFP transfected by the Lipofectamine™ 
2000 reagent (Invitrogen, CA, USA). For this aim, 5 × 106 
HEDSCs were plated in a 6-well plate to obtain a confluency 
of 80% after 24 h. Transfection efficiency was assessed using 
a helper-independent plasmid. Forty-eight hours after trans-
fection, cells were treated with 150 μg/ml of hygromycin 
B (Roche, Indianapolis, IN) to allow the growth of stable 
clones for at least 14 days. Generated green fluorescent pro-
tein (GFP) cells could be purified by fluorescent-activated 
cell sorting for GFP, and recovered in culture after sorting. 
Cell labelling and GFP transfection was confirmed by visu-
alization immediately prior to administration (Fig. 1B).
A low, middle, and high doses of stem cells  (104 cells 
µl−1, 5 × 104 cells µl−1, and  105 cells µl−1 HEDSCs dispersed 
in PBS) or vehicle were administered intranasally using a 
plastic catheter connected to a pipette (polyethylene tube; 
BD, Franklin Lakes, NJ) inserted for 2.5 mm in both nasal 
nostrils of mice during deep anesthesia. Prior stem cell or 
vehicle administration, all animals intranasally received 4µ 
hyaluronidase (Sigma Aldrich- St Louis mouse; 100 U hya-
luronidase dissolved in 24 mL of sterile PBS). Mice twice 
received 2 µL drops containing cell suspension or PBS (as 
vehicle) for each nostril. Postoperatively, to prevent immune 
rejection, all mice received daily Cyclosporine until the ani-
mals were sacrificed.
Preparation of brain sections and in vitro 
immunostaining
GFP transfected HEDSCs were visualized within the fresh 
sections of mouse brains. For this aim, after perfusion 
Fig. 1  HEDSCs and HEDSCs-GFP labelled in cell culture medium. 
A HEDSCs cultured in media demonstrate typical stromal cell mor-
phology which captured by a light microscope. B GFP transfection 
was used for labelling of HEDSCs. The labeled cells were observed 
by a fluorescence microscope
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through the left ventricle of heart with saline solution 
(50 ml, 0.9% NaCl), brain tissues were excised and frozen 
by immersion in gelatin 7.5% and sucrose 15% in PBS for 
cryosectioning by a cryostat microtome (Sakura, Tissue-tek 
cryo3 Flex microtome/cryostat). Brain coronal sections were 
placed on glass slides and visualized by using a fluorescence 
microscope (Nikon, Japan).
For immunohistochemical (IHC) analysis, all ani-
mals were perfused through with saline solution (50 ml, 
0.9% NaCl) following 200 ml of cold fixative solution 
(4% paraformaldehyde in 0.1 M PBS, pH 7.4) under deep 
anesthesia. Animals were sacrificed 120 days after HED-
SCs treatment. After perfusion, the brains were quickly 
post-fixed in the same fixative solution for 48 h at the 
room temperature. After tissue processing, brains were 
paraffin-embedded and coronal 5 μm thick serial sections 
were obtained from SNpc and corpus striatum using a 
microtome (Diapath, Italy) and were placed on silane-
coated slides. Then, sections were de-paraffinized with 
xylene and they rehydrated with 99, 96, 80, and 70% etha-
nol, respectively.
After washing in distilled water, sections were used 
for expression of GFP, Nestin, and TH markers in an IHC 
method. For this purpose, antigen retrieval was done in 
pre-heated citrate buffer (pH 6) for 22 min. After washing 
with distilled water and PBS, the endogenous peroxidase 
was blocked using 30% hydrogen peroxide for 6 min. 
Non-specific bindings were blocked by the protein block 
solution from an IHC kit (Biopharmax, KL5007, Link-
Envision, Germany) for 6 min. Subsequently, the slides 
were incubated with the primary antibody overnight at 
4 °C. Following antibodies were used in our study: 1- 
mouse monoclonal anti-TH antibody (dilution, 1:100; TH 
Antibody, F-11, sc-25269; Santa Cruz Biotechnology), 
2- GFP antibody (dilution, 1:100; GFP Antibody, B-2, 
sc-9996; Santa Cruz Biotechnology), 3- anti-human Nes-
tin (dilution, 1:100; Nestin monoclonal antibody, 10 C2; 
Thermo Fisher Scientific). After several washing with 
PBS and IHC buffer, the slides were incubated with the 
required biotinylated secondary antibody for 30 min at 
room temperature according to manufacturer’s protocol. 
All the sections were washed several times with PBS 
between each incubation, and precipitated dark brown 
was then revealed by addition of diaminobenzidine. Then, 
slides were counterstained with Meyer’s hematoxylin 
(Sigma–Aldrich).
Number of TH-positive cells in all groups was counted 
in the SNpc region. In addition, striatal TH-fiber den-
sity was measured by using Image J software (version 
1.33–1.34, National Institutes of Health, Bethesda, 
MD, USA; http://image j.nih.gov/ij/). In order to bilater-
ally evaluate the striatal dopaminergic fiber innervation, 
the Image J software was used to measure mean optical 
density (OD). Notably, the data are expressed as percent-
age of the controls.
Statistical analysis
All results are expressed as mean ± SEM and the data were 
analyzed using SPSS 19.0. software (SPSS, Inc., Chicago, 
IL, USA). Number of dopaminergic neurons, striatal OD, 
and behavioral test between all groups were analyzed by a 
one-way ANOVA test with Tukey post hoc. P-values less 
than 0.05 were considered statistically significant.
Results
Behavioral analysis
The rotational behavior test was performed to assess the 
recovery response before and after cell therapy. Our data 
revealed that intranasal administration of HEDSCs with  104 
cells µl−1, 5 × 104 cells µl−1, and  105 cells µl−1 doses into 
the striatum of 6-OHDA-injected mice could significantly 
improve the apomorphine-induced rotational behavior. Sub-
group analysis revealed that the dose 5 × 104 cells µl−1 of 
HEDSCs could improve rotational behavior more effective 
rather than two other doses (Fig. 2). The 6-OHDA adminis-
tration lead to akinesia in the PD mice at 30 ± 6 s while the 
Fig. 2  Evaluation of apomorphine-induced rotational behavior test 
after HEDSCs administration. The result showed intranasal delivery 
of HEDSCs significantly reduces rotational behavioral in days 30, 60, 
90, and 120 after cell administration. The a, b, c, and d symbols rep-
resent 6-OHDA/PBS,  104, 5 × 104, and  105 cells µl−1, respectively
4297Molecular Biology Reports (2019) 46:4293–4302 
1 3
HEDSCs-treated group displayed a significant improved per-
formance down to 8 ± 4 s. Catalepsy was evident in the ani-
mals treated with 6-OHDA with a latency period of 36 ± 3 s 
whereas the HEDSCs-treated groups displayed a signifi-
cantly better performance in a latency period of 11 ± 5 s.
To evaluate animals’ motor behavior the rotarod test was 
performed four weeks after 6-OHDA injection (pre-treat-
ment), as well as 30, 60, 90, and 120 days post cell therapy. 
The control group was showed higher performance ability 
than others. Initially, the 6-OHDA group had lower rotation 
time than the control group, and after the treatment with 
HEDSCs, the treatment groups (T1: 104 cells μl−1, T2: 5 × 
104 cells μl−1, and T3: 105 cells μl−1) showed a higher abil-
ity to stay on the rotarod compare to the pre-treatment stage. 
Thereby the treatment groups had a higher rotation time than 
6-OHDA group (Fig. 3).
Detection of HEDSCs in mouse brains
Cytoplasmic GFP labelling was used to confirm the migra-
tion of HEDSCs to corpus striatum and SNpc area. Fresh 
brain sections of treated mice with GFP-labelled cells 
Fig. 3  Rotarod for assessment 
of PD mice model following 
HEDSCs administration. The 
PD animals recovered spontane-
ously after the HEDSCs admin-
istration, showing an improve-
ment in motor function (T1: 
104 cells μl−1, T2: 5 × 104 cells 
μl−1, and T3: 105 cells μl−1). 
This test checked the latency 
time on the rotarod for 10 min 
(*** indicates p < 0.001)
Fig. 4  HEDSCs labeled cells with GFP were in the mouse brains. A 
The SNpc area that received vehicle. B The SNpc area that received 
HEDSCs in concentration 104 cells μl−1. C The corpus striatum that 
received vehicle. D The corpus striatum that received HEDSCs in 
concentration 104 cells μl−1
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showed that HEDSCs were localized in various brain areas 
such as corpus striatum and SNpc areas (Fig. 4). Also, 
IHC evaluation of fixed brain sections from treated ani-
mals revealed successful intranasal delivery of HEDSCs 
to SNpc. IHC results for detection of HEDSCs in SNpc 
revealed that the migration of HEDSCs to the SNpc was 
significantly increased by elevated dose of HEDSCs intra-
nasally administration (Fig. 5). In detail, the number of 
migrated HEDSCs was estimated significant in three fol-
lowing analyses: 5 × 104 cells µl−1 versus  104 cells µl−1, 
 105 cells µl−1 versus  104 cells µl−1, and  105 cells µl−1 ver-
sus 5 × 104 cells µl−1 (p < 0.001).
Immunohistochemistry for neuronal markers assay
6-OHDA treatment resulted in a significant decrease in the 
number of SNpc dopaminergic neurons down to 27.6 ± 3.2% 
rather than control group. Our data showed that the 
TH-expressing neuron-like cells were significantly increased 
after HEDSCs treatment. Dopaminergic neurons were sig-
nificantly recovered with the intranasal administration of 
HEDSCs compared with 6-OHDA group in three following 
doses:  104 cells µl−1, 5 × 104 cells µl−1, and  105 cells µl−1 
(p < 0.001). Subgroup analysis recognized the administration 
of HEDSCs with dose 5 × 104 cells µl−1 as the optimized 
concentration (Fig. 6). Similarly, 6-OHDA led to reduced 
corpus striatum optical density (OD) to 30.33 ± 7.41% 
compared with the control group. IHC results for TH assay 
revealed that treatment with HEDSCs in dose  104 cells µl−1 
could increase the OD percentage to 78.90 ± 7.35. Also, 
treatment in dose 5 × 104 cells µl−1 increased the OD per-
centage to 82.91 ± 7.52. Moreover, treatment in dose  105 
cells µl−1 elevated the OD percentage to 73.60 ± 7.22. The 
intranasal administration of HEDSCs could protect dopa-
minergic neurons by increased expression of TH in the cor-
pus striatum (Fig. 7). The expression of human neural Nestin 
Fig. 5  IHC results for detection of HEDSCs in SNpc. A Control 
group, B 104 cells μl−1, C 5 × 104 cells μl−1, and D 105 cells μl−1. E 
The number of HEDSCs was estimated significant in three following 
analyses: 5 × 104 cells μl−1 vs. 104 cells μl−1, 105 cells μl−1 vs. 104 
cells μl−1, and 105 cells μl−1 vs. 5 × 104 cells μl−1 (*** indicates p < 
0.001)
Fig. 6  TH-expressing neuron-like cells after HEDSCs treatment. 
A Control group. B 6-OHDA group. DA neuronal cell death in the 
SNpc was significantly increased after the injection of 6-OHDA. C 
Treatment with HEDSCs in concentration 104 cells μl−1. D Treat-
ment with HEDSCs in concentration 5 × 104 cells μl−1. E Treatment 
with HEDSCs in concentration 105 cells μl−1. F DA neurons signifi-
cantly recovered with the intranasal administration of HEDSCs in 
three doses (T1: 104 cells μl−1, T2: 5 × 104 cells μl−1, and T3: 105 
cells μl−1). *** represents the p < 0.001 which was deduced from T1, 
T2, and T3 vs. 6-OHDA group
4299Molecular Biology Reports (2019) 46:4293–4302 
1 3
was also evaluated by IHC in SNpc after HEDSCs therapy. 
IHC results revealed that the expression of human neural 
Nestin was significantly increased in 5 × 104 cells µl−1 versus 
 104 cells µl−1 and  105 cells µl−1 versus  104 cells µl−1 whereas 
it was decreased in  105 cells µl−1 versus 5 × 104 cells µl−1 
(p < 0.001; Fig. 8). 
Discussion
In the present study, we investigated the therapeutic effects 
of intranasal administration of HEDSCs in the mouse 
model of PD. Delivery of HEDSCs to the unilaterally 
6-OHDA-lesioned brain was successfully approved. In the 
lesioned area, endometrial stem cells could survive and 
also according to the pathotropism features, they are capa-
ble to migrate to the lesioned region and spontaneously dif-
ferentiate to the target cells. Pathotropism is a capacity of 
stem cells to exactly migrate to pathological regions such 
as an inflamed area [1, 26]. In this part of our study, we 
examined the intranasal administration of the endometrial 
stem cells for the first time and we found that the migra-
tion of HEDSCs to the lesioned site is dose-dependent. In 
the next step, we analyzed behavioral outcomes. Behavior 
examines are common tests to assess functional damages 
and retrieval in animal models and rotational behavior has 
Fig. 7  IHC results for TH assay 
in corpus striatum tissue sam-
ples. A Control group (%OD: 
100). B 6-OHDA group (%OD: 
30.33 ± 7.41). C Treatment 
with HEDSCs in concentration 
104 cells μl−1 (%OD: 78.90 
± 7.35). D Treatment with 
HEDSCs in concentration 5 
× 104 cells μl−1 (%OD: 82.91 
± 7.52). E Treatment with 
HEDSCs in concentration 105 
cells μl−1 (%OD: 73.60 ± 7.22). 
The intranasal administration 
of HEDSCs could protect DA 
neurons by increased expression 
of TH in the corpus striatum
Fig. 8  IHC results for cytoplasmic expression of human neural Nes-
tin in the treated animals. A Control group that received vehicle. 
B 104 cells μl−1, C 5 × 104 cells μl−1, and D 105 cells μl−1. E The 
expression of human neural Nestin was significantly increased in 5 
× 104 cells μl−1 vs. 104 cells μl−1 and 105 cells μl−1 vs. 104 cells 
μl−1 whereas it was decreased in 105 cells μl−1 vs. 5 × 104 cells μl−1 
(*** indicates p < 0.001)
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also been commonly employed as the measure of practi-
cal condition in hemi parkinsonian rodent models [27]. Our 
behavioral analysis revealed that the HEDSCs result in a 
significant improvement on behavioral parameters includ-
ing rotational behavior, rotarod test, catalepsy, and akine-
sia. In addition, we observed the concentration 5 × 104 cells 
µl−1 as an optimized dose to improve motor performance 
in PD mice model. Given the importance of progression to 
make better PD therapies, we sought to approve whether 
or not endometrial stem cells in the adult SNpc produce 
new neurons as well as dopaminergic neurons. If HEDSCs 
do produce dopaminergic neurons in the microenvironment 
of the adult midbrain, information about their ontogenesis 
would be critical to detect signaling mechanisms of neu-
rogenesis and dopaminergic neurogenesis here which may 
assist cell-replacement therapies for PD. To find molecular 
mechanisms of HEDSCs administration, we analyzed the 
expression of human neural Nestin and tyrosine hydroxy-
lase as dopaminergic neuron markers after cell therapy. 
Our data revealed that the expression of Nestin was signifi-
cantly higher in the concentration 5 × 104 cells µl−1 than  104 
cells µl−1 and  105 cells µl−1 doses. Nestin is an intermedi-
ate cytoskeletal filament that is essential for remodeling of 
cells, principally in regenerating and developing tissues. In 
the nervous system of rodents, it expresses in the majority 
of mitotically active progenitors, but it down-regulates upon 
conditions such as differentiation and then it replaced by 
other intermediate filaments [28, 29]. Also, we found similar 
outcomes about tyrosine hydroxylase in dose 5 × 104 cells 
µl−1. The protection of dopaminergic neurons in PD ani-
mal models following stem cell therapy may be inhibited by 
local micro-environmental alterations, induced by changed 
growth factors and cytokines levels, such as IL-10, whose 
transgenic expression was displayed to keep safe the levels 
of TH in the SNpc and in the striatum of 6-OHDA lesioned 
animals. Alternatively, HEDSCs could give rise to new neu-
rons locally in SNpc. The protective effects of HEDSCs in 
5 × 104 cells µl−1 may be due to improve changes in local 
microenvironments [29, 30]. For the first time, Terashima 
et al. (2018) showed the neuroprotective effects of stem cell 
factor on micro environmental neurons [29]. Stem cell factor 
can modulate the functions of microglial and stimulates the 
neuroprotective influences of microglia which may be used 
for neuronal diseases therapy. Also, other study revealed that 
MSCs stimulates the immunosuppressive features in micro-
glia, demonstrating an interesting source for the regulating 
of CNS chronic inflammation [29–31].
The major pathology of PD is the progressive degenera-
tion of dopaminergic neurons in the SNpc in the midbrain 
which send axonal projections to the corpus striatum and 
are involved in the circuits that control motor functions [32]. 
Stem cell technologies introduce new way for the treatment 
neurodegenerative disease such as PD, AD, and multiple 
sclerosis. However, there are difficulties in successfully 
administrating these stem cells. For example, after systemic 
administration, the brain-blood barrier impedes the entrance 
of stem cells into the Brain. Direct cell transplantation or 
injection may result in brain injury, and these strategies are 
less feasible. It has taken many years of intensive efforts to 
develop noninvasive effective methods to use stem cells for 
PD treatment [1]. Intranasal-delivered HEDSCs led to thera-
peutic effects on dopaminergic activity reflected by increases 
number of TH-positive neurons in the SNpc. Therefore, 
intranasal administration of HEDSCs may be a promising 
route for the treatment of PD in an optimal dose. Intrana-
sal administration of HEDSCs results in their long-term 
survival and exhibition of dopaminergic features reflected 
by their expression of TH [33, 34]. In addition, intranasal 
stem cell administration in PD has been attempted in several 
animal models with promising results [35]. This delivery 
method is also known to be involved in the rapid introducing 
of stem cells to the brain [34, 36].
By the development of stem cell technology, many cells 
such as induced pluripotent stem cells (iPSCs), embryonic 
stem cells (ESCs), neural stem cells (NSCs), and MSCs 
have been employed for new neurons derivation and dif-
ferentiation in neurological diseases. [1, 37]. Subsequent 
administration of ESCs, iPSCs and other stem cell had 
resulted in various degrees of success in PD treatment. 
However, ethical attention, difficulties in finding a con-
tinuous supply of some stem cells like ESCs, and the risk 
of tumor formation after cell therapy with ESCs or iPSCs 
can prevent their potential clinical application [17, 18, 38]. 
The endometrium presents a great source of stem cells 
with remarkable regeneration and differentiation capacity. 
Long term follows up of animals treat with endometrial 
stem cells demonstrate lack of tumorigenicity [38, 39]. In 
addition, these stem cells could be achieved in an abundant 
scale and could be easily isolated by a simple, safe, and 
painless procedure such as Pap smears without any ethical 
limitation [1]. However, in the present study, we did not 
perform multiple staining for marker evaluations which 
could be include as a limitation of our study. In addition, 
using some other specific marker such as dopamine trans-
porter could be considered for further researches.
In conclusion, the present study identified the positive 
effects of intranasal administration of HEDSCs in a pro-
gressive mouse model of PD. Therefore, HEDSCs could 
be considered as a safe, easy, and cheap strategy for non-
invasive treatment of PD.
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